Minimal residual disease (MRD) is currently the most powerful prognostic indicator in Precursor B acute lymphoblastic leukemia (B ALL). MRD analysis can be done by either ﬂow cytometric or molecular techniques. Flow cytometric detection holds potential for wider applicability than molecular techniques because ﬂow cytometric methods for leukemia diagnosis are already established at most cancer centers worldwide.